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Abstract
Background:  Coronary artery bypass grafting (CABG) is associated with high morbidity in
patients with chronic obstructive pulmonary disease (COPD).
We examine the effect of preoperative systemic corticosteroids on morbidity in this setting.
Methods: Ninety candidates for elective CABG participated in a prospective, open randomized
trial, including 30 patients with COPD who received a single injection of a long-acting
corticosteroid, 30 with COPD who received placebo, and 30 without COPD who served as
controls. Primary end-points were postoperative pulmonary and nonpulmonary complications.
Secondary end-points were length of hospital stay (LOS), ICU stay of less than 24 hours and more
than 48 hours, duration of mechanical ventilation, and time to walking and sitting.
Results: The rate of pulmonary complications was similar in the two COPD groups and in the
COPD patients and controls. The placebo group had more major nonpulmonary complications
than the treatment group, but the difference was not statistically significant (26% vs. 17%, P = NS).
The non-COPD control group had significantly fewer nonpulmonary complications than the COPD
patients (treatment+placebo) (33% vs 70%, P  = 0.014) and a similar rate of pulmonary
complications. There was a statistically significant difference between the treated and placebo
COPD groups in ICU stay less than 24 hours (P ≤ 0.001) and more than 48 hours (P = 0.03) and
hospital stay (P = 0.013). On stepwise analysis, only age and number of coronary grafts were
predictors of pulmonary complications.
Conclusion: The use of preoperative systemic corticosteroids in patients with COPD undergoing
CABG may shorten ICU and hospital stay.
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1. Background
Thoracic surgery is associated with a 10% to 40% rate of
pulmonary complications [1]. The procedure-related risk
factors include high American Society of Anesthesiologists
(ASA) class (46% complication rate for class IV vs. 10%
for class II) and long duration of surgery (73% for surgery
of > 4 hours vs. 38% for < 4 hours) [2]; the patient-related
risk factors are chronic obstructive pulmonary disease
(COPD), asthma, smoking, poor general health status,
age above 70 years, and obesity [1]. Studies have reported
mortality rates ranging from 1% to 50% in patients with
COPD and asthma undergoing coronary artery bypass
grafting (CABG) or other major surgery [2-7]. Patient ces-
sation of cigarette smoking, introduction of vigorous
lung-expansion maneuvers, administration of antibiotics
if respiratory infection is present, and treatment of airway
obstruction have all been suggested as preventive meas-
ures in these patient groups [8]. Moreover, several
researchers have shown that prophylactic treatment with
systemic corticosteroids is safe in patients with severe
asthma and COPD [2,4,9] and may help them to tolerate
surgery better with fewer complications [3,9]. This is true
even for severe corticosteroid-dependent asthmatics [9].
However, the efficacy by route of administration (sys-
temic versus inhaled corticosteroids) has not yet been
investigated [1-4,8-12]
The aim of the present study was to compare the benefit
of preoperative parenteral administration of long-acting
corticosteroids (CS) with placebo in patients with COPD
undergoing elective CABG.
2. Patients and methods
Patients
The study population consisted of 90 candidates for elec-
tive CABG, 60 with COPD and 30 with other disorders,
who were treated at the Pulmonary Institute and Depart-
ment of Thoracic and Cardiovascular Surgery of a tertiary-
care hospital between February 1, 2004 and January 31,
2005. The diagnosis of COPD was based on the American
Thoracic Society criteria; specifically, forced expiratory
volume in 1 second (FEV1) less than 70% and FEV1/forced
vital capacity (FVC) lower than 70% of predicted values
[10]. Patients were also classified according to the FEV1
based on the ATS statement [10]. Both smokers and non-
smokers were included. Patients who had an upper respi-
ratory tract infection or an exacerbation of COPD,
patients who were receiving mandatory oral (more than 5
mg) or parenteral corticosteroid treatment for one month
before the study, patients who required emergency CABG
and patients with asthma were excluded from the study.
All the study population used bronchodilators periopera-
tively.
The Human Ethics Committee of our hospital approved
the study, and all patients signed an informed consent
form prior to entry.
Procedure
Two to three weeks prior to surgery, the 60 patients with
COPD were randomly assigned to receive either a single
intramuscular injection of slow-release betamethasone
dipropionate 5 mg and rapid-release betamethasone
sodium phosphate 2 mg (Diprospan®), which is equiva-
lent to 60 mg of prednisone with a duration of action of
up to 2–6 weeks (n = 30), or placebo (NaCl 0.9% injec-
tion) (n = 30). The remaining 30 patients without COPD
served as a control group.
All other medications remained unchanged during the
study period.
Assessment
The patients were stratified by grade of left ventricular dys-
function and severity of obstructive lung disease, as deter-
mined by the ASA classification [21]. Cardiac and left
ventricular assessment was performed by echocardiogra-
phy with the SONOS-2000 device (Andover, MA, USA).
Pulmonary function was assessed with the MedGraphics-
Pulmonary Function System 1070 Series 2 (St.- Paul, MN,
USA) at the time of randomization, and with a portable
spirometer (Vitalograph, London, England) on the day
before surgery and the day of discharge.
2.4. Study end-points
Primary end-points of the study were postoperative pul-
monary complications (atelectasis, pneumonia, pneu-
mothorax, bronchospasm, retained secretion, sustained
pleural effusion and respiratory failure) and nonpulmo-
nary complications (arrhythmias, renal failure, heart fail-
ure, infections, bleeding, repeated surgery).
Secondary end-points were length of stay (LOS) in the
intensive care unit (ICU), ICU stay less than 24 hours,
ICU stay more than 48 hours, duration of mechanical ven-
tilation and chest tube use, LOS in hospital, and intensity
of rehabilitation (time to sitting and walking).
Patients were followed for 2 weeks after discharge by
either a clinic visit or a phone call.
Statistical analysis
Pearson correlation coefficients (r) and the significance
for them (p) were calculated between the variables. To
analyze statistically significant differences in categorical
variables between the study groups, chi- square test or
Fisher's exact test was used, as appropriate. To analyze sta-
tistically significant differences in mean continuous
parameters between the study groups, analysis of varianceJournal of Cardiothoracic Surgery 2007, 2:25 http://www.cardiothoracicsurgery.org/content/2/1/25
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with Duncan's multiple comparison option for pairwise
comparisons was performed. To predict the number of
pulmonary or nonpulmonary complications, a series of
stepwise linear regression models was fitted to the data.
Odds ratios were calculated from the estimates of the
model. P values less than or equal to 0.05 were considered
statistically significant.
3. Results
Baseline demographic data
All 90 patients completed the 2-week postoperative fol-
low-up.
As shown in Table 1, there were no differences among the
treatment, placebo, and control groups patients in any of
the demographic characteristics. Stratification parameters,
namely, FEV1 and left ventricular ejection fraction, and
stratification class divisions were similar in the treatment
and placebo COPD groups (Tables 1, 2). FEV1 was signif-
icantly lower in the patients with COPD than in the con-
trols (P = 0.001).
ASA class was lower in the treatment group than in the
placebo group, and significantly higher in the COPD
groups (treatment and placebo) than in the control group
(P = 0.04).
Changes in lung function
Lung function (as defined by FEV1) was similar in the
treatment and placebo groups at all three evaluation time
points: randomization, prior to surgery, and after surgery.
No significant change in mean FEV1 from the time of ran-
domization to prior to surgery was noted in any of the
groups. However, after CABG, there was a significant
decrease in FEV1 in both COPD groups (P = 0.001). Mean
FEV1 in the treatment group was 60.7% at the time of ran-
domization, 61.7% prior to surgery, and 55.3% after
CABG; corresponding rates in the placebo group were
62.6%, 64.3% and 54.7%.
Operative results
Surgery parameters, including length of operation, bypass
time and number of grafts, were similar in all three groups
(Table 3).
Primary end-points
The rates of pulmonary complications were similar in the
two COPD groups (Tables 4, 5). However, there was sig-
nificant difference in the rate of pulmonary complications
between the COPD groups (treatment+placebo) and the
control group. Although more major nonpulmonary
complications were observed in the placebo group than in
the treatment group, the difference did not reach statisti-
cal significance (P = 0.8). The patients with COPD (treat-
ment+placebo) had more nonpulmonary complications
than the patients without COPD (P = 0.014). Specifically,
the patients with COPD had a higher rate of atrial tachyar-
rhythmias (36% treatment group, 26% placebo group)
than the controls, and a higher rate of wound infections
(20% and 23%, respectively), with or without the need for
plastic reconstructive surgery (Table 5).
Secondary end-points
There was a statistically significant difference in ICU stay
less than 24 hours (P < 0.001) or more than 48 hours (P
= 0.03) between the treatment and placebo groups (Table
4). The treatment group also had a shorter LOS in hospital
than the placebo group (P  = 0.013). The duration of
mechanical ventilation was longer in the placebo than the
treatment group, but this difference did not reach statisti-
cal significance. There were no between-group differences
in chest tube time or postoperative rehabilitation (sitting
and walking) (Table 4).
Correlation analysis
The nonpulmonary complications and length of ICU stay
correlated significantly with age (P = 0.04), but not with
left ventricular dysfunction grade, length of surgery, or
bypass time. The duration of mechanical ventilation cor-
Table 1: Baseline patient characteristics
Diprospan group
(n = 30)
Placebo group
(n = 30)
Control group
(n = 30)
P value*
Male/Female, n 26/4 24/6 27/3 NS
Age, yr (mean ± SD) 67.0 ± 8.98 67.7 ± 9.2 66.4 ± 9.9 NS
Smokers/nonsmokers, n 24/6 26/4 20/10 NS
FEV1,, %
(mean ± SD)
60.6 ± 9.5 62.6 ± 8.0 88.6 ± 7.1 0.001
LVEF, %
(mean ± SD)
46.1 ± 12.4 46.1 ± 11.8 47.8 ± 10.3 NS
ASA class, n
20 0 2
31 6 2 1 2 3
4 14 9 5 0.04
*Between COPD groups (treatment+placebo) and controls.Journal of Cardiothoracic Surgery 2007, 2:25 http://www.cardiothoracicsurgery.org/content/2/1/25
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related significantly with FEV1 (P = 0.009) and no signifi-
cantly with age, left ventricular function, length of surgery,
and bypass time.
Correlation analysis showed that the risks of occurrence of
both pulmonary and nonpulmonary complications
increased with age, lower FEV1, longer ICU stay, longer
mechanical ventilation, and prolonged hospitalization.
On stepwise regression analysis, age and number of coro-
nary grafts were the most significant predictors of pulmo-
nary complications. Specifically, pulmonary
complications increased by 0.6% for each year of age and
more than twofold for every additional new graft.
4. Discussion
The results of our study are consistent with previous
reports showing that in patients with COPD, the risk of
postoperative pulmonary complications rises with older
age [1], lower FEV1 [2], and more complex coronary graft-
ing [1]. ASA class and duration of operation are also
important [13,14]. In patients who are older than 70 years
or who have peripheral vascular disease, insulin-depend-
ent diabetes mellitus, congestive heart failure, anemia, or
COPD, the postoperative mortality ranges from 11% to
19% [6]. In patients with COPD, the highest pulmonary
complication rates occur after CABG and major abdomi-
nal procedures (50%–60%) [5,15].
The most significant post-CABG complications have been
found to be heart failure with shock, arrhythmias, pulmo-
nary infection and atelectasis, stroke, renal failure, and
surgical wound infection [6,16]. Accordingly, in the
present study, the rates of nonpulmonary complications,
particularly atrial tachyarrhythmias and wound infec-
tions, were quite high in the patients with COPD. One
possible explanation is the poor general health status of
this patient population. In our series, 23 of the 60 patients
were in ASA class 4.
Sauerland et al. [17] conducted a risk benefit analysis
using a meta-analysis, to compare complication rates and
clinical advantages associated with the use of a single pre-
operative high dose of steroid in surgical patients. They
found that perioperative single-shot administration of
high dose methylprednisolone is not associated with a
significant increase in the incidence of adverse effects. In
patients with multiple fractures, limited evidence suggests
promising benefits of glucocorticoids on pulmonary com-
plications.
Michalopoulos et al. assessed the impact of history of
mild-moderate COPD on outcome in patients undergo-
ing elective CABG surgery. [18] They found that the
patients with COPD have similar morbidy and mortality
rates comparable to those of control.
Table 3: Operative data
Diprospan group Placebo group Control group P value*
Duration of surgery, hr (mean ± SD) 5.2 ± 0.97 5.1 ± 1.1 4.75 ± 0.8 NS
Duration of bypass, hr (mean ± SD) 1.7 ± 0.5 1.8 ± 0.7 1.6 ± 0.4 NS
No. of grafts (mean ± SD) 3.1 ± 0.8 3.1 ± 0.9 2.9 ± 0.8 NS
No. of LIMA bypasses 24 23 28 NS
LIMA- left internal mammary artery
*Between diprospan and placebo groups
Table 2: Distribution of patients with COPD by lung function.
LV Dysfunction
FEV1 Mild LV dysfunction (LVEF>35%) Moderate to severe LV dysfunction (LVEF<34%)
Diprospan group Placebo group Diprospan group Placebo group
50–70% 22 23 4 4
3 5 – 4 9 % 2211
<  3 4 % 1000
The classification is according to the ATS guidelines [10].
FEV1 = Forced expiratory volume at one second
LV = Left ventricular
LVEF = Left ventricular ejection fractionJournal of Cardiothoracic Surgery 2007, 2:25 http://www.cardiothoracicsurgery.org/content/2/1/25
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Regarding the benefit of preoperative steroid administra-
tion in preventing postoperative complications in patients
with COPD – for which previous data are lacking – we
failed to find any difference in the prevalence of pulmo-
nary complications between the patients given Diprospan
and the placebo group. The treated group had fewer non-
pulmonary complications than the placebo group, but the
difference did not reach statistical significance. Further-
more, the patients with COPD (either pretreated or not)
had a significantly higher rate of nonpulmonary compli-
cations than the control patients without COPD who
underwent elective CABG. The latter findings are consist-
ent with earlier studies [1,2,6,10,12] At the same time, we
found that the patients receiving steroids had both a sig-
nificantly shorter ICU stay and significantly shorter hospi-
tal stay than the patients with CPD who received placebo.
Table 5: Postoperative complications
Complications Diprospan group Placebo group Control group P value* P value*?
Pulmonary
-Bronchospasm 2 3 1
-Pneumonia 1 1 1
-Atelectasis 1 0 0
-Pleural effusion 1 0 2
-Pneumothorax 0 1 0
-Respiratory failure 1 1 1
Total pulmonary 6(20%) 6 (20%) 5 (10%) 0.56 0.02
Nonpulmonary
Major
- Wound infection 2 4 0
- Acute renal failure 1 0 0
- Stroke 1 2 0
- Sepsis 0 1 0
- Re-surgery 1 1 2
Total major 5 (17%) 8 (26%) 2 (7%) 0.8 0.03
Minor
- Atrial 11 8 1
tachyarrhythmias -
Superficial wound 4 3 4
infection
- Transient oliguria 1 2 3
- Urinary tract infection 0 1 0
- Acute gout 0 1 0
Total minor 16 (53%) 15 (50%) 8 (27%) 0.1 0.01
Total nonpulmonary 21 (70%) 23 (76%) 10 (33%) 0.79 0.01
* Between Diprospan and placebo groups.
** Between Control and COPD groups.
Table 4: Operative and postoperative course
Diprospan group (n = 30) Placebo group (n = 30) Control group (n = 30) P value*
Pulmonary complications, (%) pts. 20 20 10 NS
Nonpulmonary complications, (%) pts. 70 76 33 NS
LOS-ICU, hr (median) 93 132 34 NS
ICU<24 hours, n 19 1 3 <0.001
ICU>48 hours, n 2 8 10 0.03
Mechanical ventilation, hours (median) 55 80 32 NS
LOS-hospital, days (median) 11 13 8 0.013
Chest tube time, days (median) 3 2 2 NS
Time to sitting, days (median) 2 2 2 NS
Time to walking, days (median) 3 3 3 NS
ICU = Intensive Care Unit; LOS = length of stay
*Between Diprospan and placebo groups.Publish with BioMed Central    and   every 
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What is the possible explanation to our finding? The sys-
temic effects of the preoperative steroids may decrease the
inflammation effect and the release of pro-inflammatory
mediators like IL-1 and TNF that accompany the surgical
process. [2-5] These effects may shorten the ICU-LOS and
the mechanical ventilation period. In addition, table 2
presented higher ICU-LOS and mechanical ventilation
period in the control group. Partial explanation could be
the lack of systemic steroids in this group. Therefore, we
believe that inhaled steroids can not give the entire anti-
inflammatory effect that systemic steroids achieved.
Our study has some limitations. First, the small number
of patients may have led to a lower statistical power of the
variables. Second, the patients were followed for only 2
weeks after hospital discharge. Nevertheless, preoperative
steroids proved to be an important adjunct
In conclusion, patients with COPD are at higher risk for
post-CABG complications, particularly nonpulmonary
ones, such as atrial tachyarrhythmias and wound infec-
tion. The administration of preoperative systemic steroids
may be of benefit in reducing their postoperative ICU and
hospital stay. Larger-scale studies that include more
patients with severe COPD are needed to confirm our
results.
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